27.6675  0.368 (1.35%)		09-26 16:00
Open: 27.43 High: 27.6675 Volume: 1,367		Pre. Close: 27.3 Low: 27.41 Market Cap: 15(M)

Short term
Mid term
Targets	6-month :	32.74	1-year :	33.27
Resists	First :	28.03	Second :	28.49
Pivot price	28.01
Supports	First :	27.28	Second :	22.7
MAs	MA(5) :	27.83	MA(20) :	28.02
	MA(100) :	26.52	MA(250) :	27.07
MACD	MACD :	0.1	Signal :	0.2
%K %D	K(14,3) :	18.4	D(3) :	26.6
RSI	RSI(14): 48.1
52-week	High :	29.31	Low :	23.28

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ FTXH ] has closed above bottom band by 18.6%. Bollinger Bands are 26.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	27.73 - 27.92	27.92 - 28.08
Low:	26.95 - 27.19	27.19 - 27.4
Close:	27.3 - 27.67	27.67 - 28.01

The fund will normally invest at least 90% of its net assets (including investment borrowings) in the common stocks and depository receipts that comprise the index. The index is designed to provide exposure to U.S. companies comprising the pharmaceutical sector that have been selected based upon their liquidity and weighted based upon their cumulative score on three investing factors: volatility, value and growth. It is non-diversified.

Fri, 26 Sep 2025
Trump Slams 100% Tariff on Imported Drugs: Pharma ETFs Take a Hit - Zacks Investment Research

Mon, 08 Sep 2025
Mark Cuban Exposes How Wholesalers Force Pharmacies Into Near-Exclusive Deals, Detailing PBMs' 'Stranglehold' On Drug Pricing - Benzinga

Thu, 17 Jul 2025
ETFs to Gain on JNJ's Solid Q1 Earnings & Upbeat Outlook - Yahoo Finance

Wed, 16 Jul 2025
Trump's Pharma Tariffs Can Hit Novo Nordisk, Says Barclays Expert, But It's 'Difficult' To Predict As Drugmakers Have 'Complex Supply Chains' - Sahm

Fri, 11 Jul 2025
Trump Threatens 200% Pharma Tariffs, But Analyst Says This Stock Is Immune And Expected To 'Benefit' From Levies - Benzinga

Fri, 20 Jun 2025
Mark Cuban Corrects Elizabeth Warren As She Slams JNJ, PFE For Higher Prices And Zero Taxes On Big Pharma: 'PBMs Corrupt Healthcare' - AbbVie (NYSE:ABBV), Amgen (NASDAQ:AMGN) - Benzinga

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Neutral
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Neutral
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Neutral
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Neutral
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Neutral

Exchange: NASDAQ
Sector: Financial Services
Industry: Asset Management
Shares Out	0 (M)
Shares Float	0 (M)
Held by Insiders	0 (%)
Held by Institutions	0 (%)
Shares Short	0 (K)
Shares Short P.Month	0 (K)

EPS	0
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	0 %
Return on Equity (ttm)	0 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	0
Qtrly Earnings Growth	0 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	0 (M)

PE Ratio	0
PEG Ratio	0
Price to Book value	0
Price to Sales	0
Price to Cash Flow	0

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.